New data from a pooled analysis of the ADvocate1 and ADvocate2 trials indicates lebrikizumab was efficacious for treating atopic dermatitis (AD) over a year-long period.

“Lebrikizumab demonstrated significant improvement versus placebo for measures of skin clearance and patient reported outcomes at weeks 16 and 52 in patients with AD,” the authors wrote. “[Here] we report weekly maintained effect of lebrikizumab from weeks 16-52 on itch and sleep disturbance assessed by the Patient-Oriented Eczema Measure (POEM) in 2 phase 3 clinical trials.”

The researchers rerandomized (2:2:1) week-16 responders (defined as EASI75 or IGA 0/1 with ≥2-point improvement and without rescue medication) to lebrikizumab every 2 weeks (LEBQ2W), every 4 weeks (LEBQ4W), or placebo for 36 additional weeks. The researchers used the Patient-Oriented Eczema Measure (POEM) to assess itch and sleep disturbance. The maintenance of improvement in patients achieving POEM response 0/1 for both itch and sleep disturbance were captured in electronic diaries for weeks 16-52 for both treatment groups.

According to the analysis, POEM responses of 0/1 were maintained week-by-week from the electronic diaries filled out by the patients. The proportions of patients responding to POEM for itch at weeks 16 and 52 were 35.9% and 44.6% for LEBQ2W, respectively, and 39.3% and 48.0% for LEBQ4W, respectively. For sleep disturbance, the proportions of patients responding 0/1 to POEM at weeks 16 and 52 were 66.0% and 83.1% for the LEBQ2W group, respectively, with 72.6% and 78.4% in the for LEBQ4W arm, respectively.  

“POEM 0/1 responses for itch and sleep disturbance were maintained between patient study visits and improved over 52 weeks in lebrikizumab-treated patients, demonstrating maintenance of response for key AD symptoms,” the authors concluded.

Results of the analysis were published in the SDPA Annual Summer Conference supplement of the Journal of Dermatology for Physician Assistants.

Source: Yosipovitch G, et al. Journal of Dermatology for Physician Assistants. 2024. Doi:10.1097/jdpa.0000000000000020